Gamgertamig poster accepted for presentation at the 2026 ASH1 Annual Meeting, featuring data from ongoing Phase 1b studies that suggest potential to retain remission after B cell reconstitution, maintained in the absence of background therapy for autoimmune cytopenias, consistent with an "immune reset"
Year-end 2026 guidance for cash and financial investments of at least €2B, including initiating a second €50M share repurchase program
Mechelen, Belgium; November 11, 2026, 22.01 CET; regulated information - Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today reported its financial results for the first nine months of 2026 and provided a business update.
"At ASH, we look forward to sharing results from patients enrolled in company-sponsored trials, which we believe will further characterize the differentiated efficacy and safety profile of gamgertamig and its potential as a first- and best-in-class T-cell engager in autoimmune disease," said Henry Gosebruch, Chief Executive Officer of Lakefront.
"Our guidance for year-end 2026 cash and financial investments is at least €2 billion, including the recently completed share repurchase program and taking into account the decision to initiate a second €50 million share repurchase program, which is expected to be completed by the end of the first quarter of 2027," added Aaron Cox, Chief Financial Officer of Lakefront.
1 American Society of Hematology
Third Quarter 2026 Business Update
CORPORATE
- Lakefront completed a €50 million share repurchase program on October 16, 2026. Under this completed program, 1.99 million shares were repurchased at an average price of €25.19.
- Dr. Mehdi Shahidi has been appointed as Non-Executive Independent Board Director. He replaces Dr. Paulo Fontoura, who resigned from the Lakefront Board in July 2026 following his appointment as Global Head of R&D at Sanofi.
IMMUNOLOGY PORTFOLIO
- A gamgertamig poster presentation highlighting data from ongoing Phase 1b studies that suggest potential to retain remission after B cell reconstitution, maintained in the absence of background therapy for autoimmune cytopenias, consistent with an "immune reset", has been accepted for the 2026 American Society of Hematology (ASH) Meeting. Investor webcast scheduled for Monday, December 14, 2026, at 8:00 AM ET.
- Gamgertamig has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (U.S. FDA) for the treatment of pemphigus. Gamgertamig was previously granted both Fast Track and Orphan Drug Designation by the U.S. FDA for the treatment of autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP).
- Gamgertamig is expected to enter registrational studies in 2027.
- Ongoing Lakefront-sponsored clinical trials of gamgertamig in autoimmune diseases are actively enrolling, and expansion of the clinical trials program is anticipated in 2027.
- Phase 1b study with gamgertamig in patients with autoimmune cytopenias (including ITP and AIHA) (NCT07083960), active in Australia and the United States.
- Phase 1b study with gamgertamig in seropositive autoimmune diseases (including idiopathic inflammatory myositis, Sjögren's disease, pemphigus vulgaris (PV), and pemphigus foliaceus (PF)) (NCT07229144), active in Australia, New Zealand, Czech Republic, and Japan.
- Multicenter, long-term follow-up study in participants who previously participated in a gamgertamig clinical study (NCT07847892) initiated in September 2026.
- Lakefront expects to initiate proof-of-concept basket studies assessing gamgertamig in additional autoimmune indications in the first half of 2027.
- In addition, Keymed is conducting a number of company-sponsored studies in Greater China with gamgertamig in both malignant and autoimmune indications.
- Lakefront continues to progress the preclinical portfolio of three autoimmune and inflammatory disease programs originally from Ouro Medicines (Ouro) with an opt-in for Gilead Sciences (Gilead) for a 50/50 profit split post clinical proof-of-concept for $75 million per program.
- GLPG3667 discontinuation: Lakefront has completed a rigorous analysis of the competitive landscape and market opportunity. Following extensive discussions with potential strategic partners, the Company has decided to discontinue the program. The cost associated with this discontinuation is not expected to be material.
ONCOLOGY CAR-T CELL THERAPY UPDATE
- The Company announced the start of the wind-down of its cell therapy activities in January 2026. At the date of this press release, the wind-down is substantially complete, with the last wave of departures of impacted personnel expected before year-end and limited remaining costs for the fourth quarter of 2026 and beyond, primarily associated with the HESPERIA study.
- To support long-term patient follow-up, the HESPERIA study continues to monitor safety of all patients treated in the discontinued parent studies; associated spending is expected to remain minimal.
Post-period Event
- On October 14, 2026, Lakefront completed the sale of its next-generation early-stage cell therapy pipeline to Armed Cell Therapeutics BV for €8 million upfront and the potential for up to $230 million in milestone payments and a low-single-digit royalty to Lakefront. This program is based on technology originated from and research undertaken by AboundBio, which was acquired by Lakefront Biotherapeutics NV (previously Galapagos NV) in 2022.
- The Board of Directors of Lakefront has approved a second €50 million share repurchase program. This second share repurchase program will be initiated shortly, with completion expected by the end of the first quarter of 2027. For further details, we refer to the press release to be issued upon launch of the program.
Financial Guidance
- The Company expects its year-end 2026 cash and financial investments balance to be in the range of €2.0 to €2.05 billion. This guidance includes initiating a second €50 million share repurchase program, which was not considered in the previous guidance range.
- Lakefront forecasts having at least €1.6 billion of its cash remaining for additional strategic transactions and other capital allocation priorities following funding the portfolio to first gamgertamig approval.
- Lakefront expects to change the presentation currency of its consolidated financial statements for the year ending December 31, 2026, from the euro to the U.S. dollar, and to change the functional currency from the euro to the U.S. dollar effective January 1, 2027. These changes are intended to better reflect the increasingly U.S. dollar-denominated nature of the Company's operations and financial profile.
- All guidance figures assume a EUR/USD exchange rate of 1.175, consistent with year-end 2025 and prior guidance. As of September 30, 2026, the EUR/USD exchange rate was 1.1355.
- These estimates are subject to change and depend on exchange rate fluctuations and future business development activity.
Financial Performance
Key figures for the first nine months of 2026 (consolidated)
(€ millions, except basic & diluted earnings/loss (-) per share)
| Nine months ended September 30, | % Change | ||
| 2026 | 2025 | ||
| Supply revenues | 17.7 | 29.3 | -40% |
| Collaboration revenues | 8.4 | 182.1 | -95% |
| Total net revenues | 26.1 | 211.4 | -88% |
| Cost of sales | (17.6) | (29.3) | -40% |
| R&D expenses | (82.5) | (351.9) | -77% |
| G&Ai and S&Mii expenses | (76.6) | (109.0) | -30% |
| Impairment of the cell therapy activities | (204.8) | ||
| Other operating income | 2.2 | 21.4 | -90% |
| Operating loss | (148.4) | (462.2) | -68% |
| Fair value adjustments and net exchange differences | 119.0 | (50.5) | |
| Net other financial result | 37.1 | 30.4 | |
| Income taxes | (0.2) | 19.3 | |
| Net profit/loss (-) from continuing operations | 7.5 | (463.0) | |
| Net profit from discontinued operations, net of tax | 6.4 | 1.7 | |
| Net profit/loss (-) of the period | 13.9 | (461.3) | |
| Basic and diluted earnings/loss (-) per share (€) | 0.2 | (7.0) | |
| Financial investments, cash and cash equivalents | 2,183.1 | 3,050.1 | |
Details of the financial results for the first nine months of 2026
Total operating loss from continuing operations for the first nine months of 2026 amounted to €148.4 million, compared to an operating loss of €462.2 million for the first nine months of 2025. The operating loss in 2025 was negatively impacted by an impairment on the cell therapy activities of €204.8 million as a result of the Company's announced strategic alternatives process for the cell therapy activities, and the executed strategic reorganization announced in January 2025, for €135.5 million. The latter was reflected in severance costs of €47.5 million, costs for early termination of collaborations of €45.5 million, impairment on fixed assets related to small molecules activities of €9.5 million, professional services costs of €21.4 million, €9.8 million accelerated non-cash cost recognition for subscription right plans and €1.8 million other operating expenses.
- Total net revenues amounted to €26.1 million for the first nine months of 2026, compared to €211.4 million for the first nine months of 2025. The revenue recognition related to the exclusive access rights granted to Gilead for Lakefront's drug discovery platform amounted to €172.6 million for the first nine months of 2025. The deferred income related to the drug discovery platform was fully released in revenue at the end of 2025.
- Cost of sales amounted to €17.6 million for the first nine months of 2026, compared to €29.3 million for the first nine months of 2025, and related to the supply of Jyseleca to Alfasigma under the transition agreement. The related revenues are reported in total net revenues.
- R&D expenses amounted to €82.5 million for the first nine months of 2026, compared to €351.9 million for the first nine months of 2025. In the first nine months of 2025, the Company recorded increased personnel expenses (mainly related to severance costs), an impairment on fixed assets (related to small molecules programs) and a provision for early termination of collaboration agreements. Additionally, due to the wind-down of the cell therapy activities, the spending in the CAR-T programs decreased in the first nine months of 2026 as compared to the first nine months of 2025.
- G&A and S&M expenses amounted to €76.6 million for the first nine months of 2026, compared to €109.0 million for the first nine months of 2025. This decrease was mainly due to lower personnel costs (primarily severance costs).
- Impairment of the cell therapy activities in 2025 is a result of the Company's previously announced strategic alternatives process for the cell therapy activities whereby the Company assessed the recoverable amount of the cell therapy activities' associated assets in accordance with International Accounting Standard 36. The recoverable amount was estimated to be lower than the assets' carrying value. As a result, the Company recognized an impairment loss of €204.8 million for the first nine months of 2025, thereby aligning the cell therapy assets' book value with the Company's strategic intention to wind down the cell therapy activities, which resulted in a full impairment of both the associated goodwill and intangible assets and a partial impairment of property, plant and equipment.
- Other operating income amounted to €2.2 million for the first nine months of 2026, compared to €21.4 million for the first nine months of 2025, mainly driven by lower R&D incentives income.
Net financial income amounted to €156.1 million for the first nine months of 2026, compared to net financial loss of €20.1 million for the first nine months of 2025.
- Fair value adjustments and net currency exchange results amounted to a positive amount of €119.0 million for the first nine months of 2026, compared to a negative amount of €50.5 million for the first nine months of 2025, and were primarily attributable to €68.3 million of positive changes in fair value of financial investments and €42.0 million of unrealized currency exchange gains on Lakefront's cash and cash equivalents and financial investments at amortized cost in U.S. dollars.
- Net other financial income amounted to €37.1 million for the first nine months of 2026, compared to net other financial income of €30.4 million for the first nine months of 2025. Interest income amounted to €35.6 million for the first nine months of 2026, compared to €31.4 million of interest income for the first nine months of 2025. Fair value gains and interest income derived from cash, cash equivalents and financial investments excluding any currency exchange results amounted to €68.2 million for the first nine months of 2026 (compared to €77.2 million for the same period last year).
Income taxes amounted to a negative amount of €0.2 million for the first nine months of 2026, compared to positive income taxes of €19.3 million in the same period last year. The major amount in 2025 can be mainly explained by the reversal of the deferred tax liabilities linked to capitalized intangible assets related to the cell therapy activities, as the Company recorded an impairment on these intangible assets.
The Company reported a net profit from continuing operations of €7.5 million for the first nine months of 2026, compared to a net loss from its continuing operations of €463.0 million for the first nine months of 2025.
Net profit from discontinued operations related to Jyseleca amounted to €6.4 million for the first nine months of 2026, compared to net profit amounting to €1.7 million for the first nine months of 2025.
Lakefront reported a net profit of €13.9 million for the first nine months of 2026, compared to a net loss of €461.3 million for the first nine months of 2025.
Cash position
Financial investments and cash and cash equivalents totaled €2,183.1 million on September 30, 2026, as compared to €2,998.0 million on December 31, 2025. The cash and cash equivalents and financial investments included $2,150.2 million held in U.S. dollars ($2,159.0 million on December 31, 2025) which could generate foreign exchange gains or losses in the financial results in accordance with the fluctuation of the EUR/U.S. dollar exchange rate as the Company's functional currency is EUR (translated at a rate of 1.1355 €/$ at September 30, 2026).
Total net decrease in cash and cash equivalents and financial investments amounted to €814.9 million during the first nine months of 2026, compared to a net decrease of €267.7 million during the first nine months of 2025. This net decrease was composed of (i) €97.2 million of operational cash burniii, which includes cash in of €88.2 million related to the return on financial investments, (ii) €58.4 million of positive exchange rate differences, positive changes in fair value of current financial investments, variation in accrued interest income, (iii) €1.1 million, which includes acquisition of equity investments and the issuance of a convertible loan, (iv) €6.1 million of net cash in related to the sale of subsidiaries, (v) €40.8 million purchase of own shares and (vi) €740.3 million cash out related to the purchase of Ouro Medicines.
Corporate Calendar 2027
| Date | Event |
| February 24, 2027 | Full-year results 2026 |
| March 25, 2027 | Annual report 2026 |
| April 27, 2027 | Annual General Shareholders' Meeting |
| May 3, 2027 | First quarter results 2027 |
| August 4, 2027 | Half-year results 2027 |
| November 3, 2027 | Third quarter results 2027 |
About Lakefront Biotherapeutics
Lakefront Biotherapeutics is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical-stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first-in-class and best-in-class BCMAxCD3 T-cell engager for autoimmune diseases. Backed by deep deal-making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high-quality assets with clear potential to deliver meaningful patient impact and long-term shareholder value. For more information, visit www.lakefrontbio.com or follow us on LinkedIn or X.
For further information, contact Lakefront Biotherapeutics:
Investor Relations
Sherri Spear
+1 412 522 6418
sherri.spear@lakefrontbio.com
Richie Livingston
+1 312 636 7072
richie.livingston@lakefrontbio.com
Forward-looking statements
This press release contains forward-looking statements, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as "believe," "anticipate," "expect," "intend," "plan," "seek," "upcoming," "future," "estimate," "may," "will," "could," "would," "potential," "forward," "goal," "next," "continue," "should," "encouraging," "aim," "progress," "remain," "explore," "further" as well as similar expressions. These statements include, but are not limited to, the guidance from management regarding Lakefront's financial results and statements related to Lakefront's business and financial condition, including Lakefront's cash position (including guidance regarding the expected results and operational use of cash for the fiscal year 2026 and statements regarding foreign exchange gains or losses in accordance with the fluctuations of the EUR/U.S. dollar exchange rate); statements regarding Lakefront's business development strategy, including statements regarding the proposed use and allocation of Lakefront's capital resources, statements regarding the expected transition of Lakefront's functional currency from the euro to the U.S. dollar, statements regarding the post-closing operations and benefits of the transaction with Gilead and Ouro, statements regarding the wind-down of Lakefront's cell therapy activities, including statements related to the timing, costs, and completion thereof, statements regarding Lakefront's plans to repurchase ordinary shares, including statements related to the amount, timing and completion of the second share repurchase program, and statements regarding the sale of Lakefront's early-stage cell therapy pipeline to Armed Cell Therapeutics and the expected benefits of such sale; statements regarding the potential attributes and benefits of Lakefront's product candidates and partnered and licensed programs, including statements related to the potential attributes and benefits of the early-stage cell therapy pipeline, statements regarding gamgertamig's Phase 1b and proof-of-concept basket studies, including statements related to the expected timing, design and readouts of the gamgertamig studies and the expected benefits and potential of gamgertamig and BCMA targeted T-cell engagers and statements regarding Lakefront's investments in other companies; statements regarding Lakefront's future product candidates or approved products, if any, including statements regarding the expected timing, design and readouts of Lakefront's ongoing and planned preclinical studies and clinical trials, including recruitment for trials and interim or topline results for trials and studies in Lakefront's portfolio, statements regarding the potential attributes and benefits of Lakefront's product candidates and statements regarding Lakefront's commercialization efforts for Lakefront's product candidates and any of Lakefront's future approved products, if any; and statements regarding the discontinuation of GLPG3667, including the expected costs and benefits of such discontinuation. Lakefront cautions the reader that forward-looking statements are based on management's current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity, performance or achievements, or the industry in which Lakefront operates, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if Lakefront's results, performance, financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, the risk that Lakefront's expectations and management's guidance regarding Lakefront's 2026 operating expenses, cash position and other financial estimates may be incorrect (including because one or more of the assumptions underlying Lakefront's revenue or expense expectations may not be realized); the risks associated with the changes to Lakefront's capital allocation strategies; the risks associated with the expected transition of Lakefront's functional currency from the euro to the U.S. dollar; the risk that Lakefront is not able to realize the benefits ofLakefront's transaction with Gilead, including with respect to Ouro; the risk that Lakefront will not be able to execute on Lakefront's currently contemplated business plan or strategy and/or will revise Lakefront's business plan or strategy; risks related to Lakefront's ability to successfully identify, pursue and consummate new transformational business development transactions, including Lakefront's ability to identify product candidates that will have commercial success and/or be profitable; risks related to our ability to satisfy legal and regulatory requirements (including antitrust requirements related to both us and Gilead), amend our existing agreement with Gilead, and address other factors outside our control that may impact our ability to consummate any potential transaction timely or at all, or if consummated, to realize the benefits of such transaction; the risks related to our ability to successfully implement the wind down of our cell therapy activities within the expected timeframe or at all, or if implemented, will achieve its anticipated economic benefits; risks related to negative impacts of the wind down (whether or not completed) on our stock price, employee retention, business relationships and business generally (including risk of litigation); risks associated with Lakefront's product candidates and partnered and licensed programs; the risk that ongoing and future clinical trials may not be completed in the currently envisaged timelines or at all; the inherent risks and uncertainties associated with competitive developments, clinical trials, recruitment of patients, product development activities and regulatory approval requirements (including the possibility of unfavorable new clinical data and further analyses of existing clinical data, the risks related to clinical failure at any stage of clinical development; uncertainty inherent to patient enrollment and enrollment rate, Lakefront's ability to use and expand Lakefront's drug discovery efforts, competition, side effects caused by our product candidates, delays in obtaining regulatory approval of manufacturing processes and facilities or disruptions in manufacturing processes, and the rate and degree of market acceptance of Lakefront's products, if approved), the possibility of differing perspectives and requirements by local regulatory authorities, and new or changing government regulations; risks related to the commercialization of Lakefront's products, if approved; risks related to Lakefront's ability to implement Lakefront's business model, strategic plans for Lakefront's business, product candidates and technology; risks related to the scope of protection we are able to establish and maintain for intellectual property rights covering Lakefront's product candidates and technology; risks related to Lakefront's ability to enter into strategic arrangements and strategic collaboration agreements; risks related to Lakefront's ability to maintain and establish collaborations; risks related to Lakefront's ability to attract and retain qualified employees and key personnel; risks related to Lakefront's reliance on collaborations with third parties (including, but not limited to, Lakefront's collaboration partner Gilead); the risk that Lakefront's estimates regarding the commercial potential of Lakefront's product candidates (if approved) or expectations regarding the costs and revenues associated with the commercialization rights may be inaccurate; and risks related to geopolitical conflicts and macro-economic events. A further list and description of these risks, uncertainties and other risks can be found in Lakefront's filings and reports with the Securities and Exchange Commission (SEC), including in Lakefront's most recent annual report on Form 20-F filed with the SEC and Lakefront's subsequent filings and reports filed with the SEC. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if the results of Lakefront's operations, financial condition and liquidity, or the industry in which Lakefront operates, are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of this release. Lakefront expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in Lakefront's expectations or any change in events, conditions or circumstances, unless specifically required by law or regulation.
i General and administrative
ii Sales and marketing
iii The operational cash burn (or operational cash flow if this liquidity measure is positive) is equal to the increase or decrease in the cash and cash equivalents (excluding the effect of exchange rate differences on cash and cash equivalents), minus:
- the net proceeds, if any, from share capital and share premium increases included in the net cash flows generated from/used in (-) financing activities;
- the net proceeds or cash used, if any, related to the acquisitions or disposals of businesses; the acquisition of financial assets held at fair value through other comprehensive income; the movement in restricted cash and movement in financial investments, if any, the cash advances and loans given to third parties, if any, included in the net cash flows generated from/used in (-) investing activities;
- the cash used for other liabilities related to the acquisition or disposal of businesses, if any, included in the net cash flows generated from/used in (-) operating activities; and
- the cash used for the purchase of own shares.
This alternative liquidity measure is in the view of the Company an important metric for a biotech company in the development stage. The operational cash burn for the first nine months of 2026, amounted to €97.2 million and can be reconciled to the cash flow statement by considering the increase in cash and cash equivalents of €0.2 million, adjusted by (i) the net sale of financial investments amounting to €873.5 million, (ii) the cash-in related to the sale of subsidiaries of €6.1 million, (iii) the acquisition of equity investments and issuance of a convertible loan amounting to €1.1 million, (iv) the purchase of own shares of €40.8 million and (v) the cash out from the acquisition of Ouro Medicines of €740.3 million.
Addendum
Consolidated statements of income and comprehensive income/loss (-) (unaudited)
Consolidated income statement
| Nine months ended September 30 | |||
| (thousands of €, except per share data) | 2026 | 2025 | |
| Supply revenues | 17,726 | 29,332 | |
| Collaboration revenues | 8,443 | 182,094 | |
| Total net revenues | 26,169 | 211,426 | |
| Cost of sales | (17,621) | (29,281) | |
| Research and development expenses | (82,498) | (351,909) | |
| General and administrative expenses, and sales and marketing expenses | (76,601) | (109,017) | |
| Impairment of the cell therapy activities | - | (204,753) | |
| Other operating income | 2,165 | 21,374 | |
| Operating loss | (148,386) | (462,160) | |
| Fair value adjustments and net currency exchange differences | 119,037 | (50,565) | |
| Other financial income | 37,673 | 32,470 | |
| Other financial expenses | (537) | (2,029) | |
| Profit/loss (-) before tax | 7,787 | (482,284) | |
| Income taxes | (245) | 19,287 | |
| Net profit/loss (-) from continuing operations | 7,542 | (462,997) | |
| Net profit from discontinued operations, net of tax | 6,388 | 1,735 | |
| Net profit/loss (-) | 13,930 | (461,262) | |
| Net profit/loss (-) attributable to: | |||
| Owners of the parent | 13,930 | (461,262) | |
| Basic and diluted earnings/loss (-) per share | 0.21 | (7.00) | |
| Basic and diluted earnings/loss (-) per share from continuing operations | 0.12 | (7.03) | |
| Consolidated statement of comprehensive income/loss (-) | |||
| Nine months ended September 30 | |||
| (thousands of €) | 2026 | 2025 | |
| Net profit/loss (-) | 13,930 | (461,262) | |
| Items that will not be reclassified subsequently to profit or loss: | |||
| Fair value adjustment financial assets held at fair value through other comprehensive income | 808 | (6,130) | |
| Items that may be reclassified subsequently to profit or loss: | |||
| Translation differences, arisen from translating foreign activities | 9,895 | (414) | |
| Other comprehensive income/loss (-), net of income tax | 10,703 | (6,544) | |
| Total comprehensive income/loss (-) attributable to: | |||
| Owners of the parent | 24,633 | (467,806) | |
| Total comprehensive income/loss (-) attributable to owners of the parent arises from: | |||
| Continuing operations | 18,245 | (469,541) | |
| Discontinued operations | 6,388 | 1,735 | |
| Total comprehensive income/loss (-), net of income tax | 24,633 | (467,806) | |
Consolidated statements of financial position (unaudited)
| (thousands of €) | September 30, 2026 | December 31, 2025 |
| Assets | ||
| Intangible assets | 754,260 | 848 |
| Property, plant and equipment | 75,694 | 80,663 |
| Deferred tax assets | 99 | 195 |
| Non-current R&D incentives receivables | 93,627 | 126,662 |
| Non-current contingent consideration receivable | 46,024 | 47,750 |
| Equity investments | 74,022 | 46,809 |
| Other non-current assets | 2,645 | 2,959 |
| Convertible loan | 62 | 21,175 |
| Non-current assets | 1,046,433 | 327,061 |
| Inventories | 4,867 | 22,493 |
| Trade and other receivables | 20,616 | 20,706 |
| Current R&D incentives receivables | 32,720 | 31,208 |
| Current financial investments | 2,088,484 | 2,910,180 |
| Cash and cash equivalents | 94,655 | 87,868 |
| Other current assets | 5,689 | 7,002 |
| Current assets from continuing operations | 2,247,031 | 3,079,457 |
| Assets in disposal group classified as held for sale | 1,104 | - |
| Total current assets | 2,248,135 | 3,079,457 |
| Total assets | 3,294,568 | 3,406,518 |
| Equity and liabilities | ||
| Share capital | 293,937 | 293,937 |
| Share premium account | 2,736,994 | 2,736,994 |
| Other reserves | (7,829) | (8,637) |
| Translation differences | 12,892 | 2,997 |
| Own shares | (42,602) | - |
| Accumulated result | 239,370 | 210,577 |
| Total equity | 3,232,762 | 3,235,868 |
| Non-current lease liabilities | 1,828 | 5,186 |
| Other non-current liabilities | 11,648 | 12,601 |
| Non-current liabilities | 13,476 | 17,787 |
| Current lease liabilities | 1,272 | 1,729 |
| Trade and other liabilities | 45,647 | 104,647 |
| Provisions | 1,102 | 45,499 |
| Current tax payable | 276 | 956 |
| Current deferred income | 33 | 32 |
| Current liabilities | 48,330 | 152,863 |
| Total liabilities | 61,806 | 170,650 |
| Total equity and liabilities | 3,294,568 | 3,406,518 |
Consolidated cash flow statements (unaudited) | ||
| Nine months ended September 30 | ||
| (thousands of €) | 2026 | 2025 |
| Net profit/loss (-) of the period | 13,930 | (461,262) |
| Impairment of the cell therapy activities | - | 204,753 |
| Decrease/increase (-) in provisions | (44,396) | 33,722 |
| Adjustment for non-cash transactions | (109,268) | 142,672 |
| Adjustment for items to disclose separately under operating cash flow | (34,591) | (49,726) |
| Adjustment for items to disclose under investing and financing cash flows | (8,156) | (37,259) |
| Change in working capital other than deferred income | (1,511) | 112,140 |
| Cash used for other liabilities related to the acquisition of subsidiaries | - | (1,792) |
| Decrease in deferred income | - | (174,921) |
| Cash used in operations | (183,992) | (231,673) |
| Interest paid | (166) | (386) |
| Interest received | 33,450 | 22,310 |
| Corporate taxes paid | (1,435) | (246) |
| Net cash flows used in operating activities | (152,143) | (209,995) |
| Purchase of property, plant and equipment | (303) | (12,100) |
| Purchase of intangible fixed assets | - | (155) |
| Proceeds from disposal of property, plant and equipment | 2,673 | 76 |
| Purchase of financial investments | (1,381,714) | (3,051,834) |
| Investment income received related to financial investments | 54,731 | 55,376 |
| Sale of financial investments | 2,255,249 | 3,204,274 |
| Proceeds from settlement of hedging instrument | - | 22,745 |
| Convertible loan issued to third party | (62) | (20,000) |
| Cash in from the disposal of subsidiaries, net of cash disposed of | 6,107 | 17,809 |
| Cash out from acquisition of subsidiaries, net of cash acquired | (740,322) | - |
| Acquisition of equity investments held at fair value through other comprehensive income | (1,031) | - |
| Net cash flows generated from investing activities | 195,328 | 216,191 |
| Payment of lease liabilities | (2,143) | (2,868) |
| Purchase of own shares | (40,776) | - |
| Net cash flows used in financing activities | (42,919) | (2,868) |
| Increase in cash and cash equivalents | 266 | 3,328 |
| Cash and cash equivalents at beginning of the period | 87,868 | 64,239 |
| Increase in cash and cash equivalents | 266 | 3,328 |
| Effect of exchange rate differences on cash and cash equivalents | 6,521 | (3,109) |
| Cash and cash equivalents at end of the period | 94,655 | 64,458 |
Consolidated statements of changes in equity (unaudited)
| (thousands of €) | Share capital | Share premium account | Own shares | Translation differences | Other reserves | Accumulated result | Total |
| On January 1, 2025 | 293,937 | 2,736,994 | - | 3,472 | (3,158) | (134,306) | 2,896,939 |
| Net loss | (461,262) | (461,262) | |||||
| Other comprehensive loss | (414) | (6,130) | (6,544) | ||||
| Total comprehensive loss | (414) | (6,130) | (461,262) | (467,806) | |||
| Share-based compensation | 17,830 | 17,830 | |||||
| On September 30, 2025 | 293,937 | 2,736,994 | - | 3,058 | (9,288) | (577,738) | 2,446,963 |
| On January 1, 2026 | 293,937 | 2,736,994 | - | 2,997 | (8,637) | 210,577 | 3,235,868 |
| Net profit | 13,930 | 13,930 | |||||
| Other comprehensive income/loss (-) | 9,895 | 808 | 10,703 | ||||
| Total comprehensive income/loss (-) | 9,895 | 808 | 13,930 | 24,633 | |||
| Purchase of own shares | (42,602) | (42,602) | |||||
| Share-based compensation | 14,863 | 14,863 | |||||
| On September 30, 2026 | 293,937 | 2,736,994 | (42,602) | 12,892 | (7,829) | 239,370 | 3,232,762 |
Attachment
- PR_Q3 26_EN_vF
